|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
EP0171407B1
(en)
|
1984-01-30 |
1993-11-18 |
Imperial Cancer Research Technology Limited |
Improvements relating to growth factors
|
|
US5401638A
(en)
|
1986-06-04 |
1995-03-28 |
Oncogene Science, Inc. |
Detection and quantification of neu related proteins in the biological fluids of humans
|
|
US4968603A
(en)
|
1986-12-31 |
1990-11-06 |
The Regents Of The University Of California |
Determination of status in neoplastic disease
|
|
CA1339946C
(en)
|
1987-03-31 |
1998-07-07 |
Michael J. Griffith |
Ultrapurification process for polypeptides
|
|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US5720937A
(en)
|
1988-01-12 |
1998-02-24 |
Genentech, Inc. |
In vivo tumor detection assay
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
DK0474727T3
(da)
|
1989-05-19 |
1998-01-12 |
Genentech Inc |
HER2 ekstracellulært domæne
|
|
WO1991005264A1
(en)
|
1989-09-29 |
1991-04-18 |
Oncogenetics Partners |
Detection and quantification of neu related proteins in the biological fluids of humans
|
|
US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
|
IL101943A0
(en)
|
1991-05-24 |
1992-12-30 |
Genentech Inc |
Structure,production and use of heregulin
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
AU675916B2
(en)
|
1991-06-14 |
1997-02-27 |
Genentech Inc. |
Method for making humanized antibodies
|
|
EP0604580A1
(en)
|
1991-09-19 |
1994-07-06 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
|
|
ES2434840T3
(es)
|
1995-07-27 |
2013-12-17 |
Genentech, Inc. |
Formulación de proteína liofilizada isotónica estable
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
|
US7371376B1
(en)
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
|
EP0852951A1
(de)
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
|
|
ES2335365T3
(es)
|
1996-11-27 |
2010-03-25 |
Genentech, Inc. |
Purificacion por afinidad de polipeptido en una matriz de proteina a.
|
|
US5994071A
(en)
|
1997-04-04 |
1999-11-30 |
Albany Medical College |
Assessment of prostate cancer
|
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
CA2324494A1
(en)
|
1998-03-27 |
1999-09-30 |
Genentech, Inc. |
Apo-2 ligand-anti-her-2 antibody synergism
|
|
ES2261589T3
(es)
|
1998-05-06 |
2006-11-16 |
Genentech, Inc. |
Composicion de anticuerpos anti-her2.
|
|
US6573043B1
(en)
|
1998-10-07 |
2003-06-03 |
Genentech, Inc. |
Tissue analysis and kits therefor
|
|
EP1187632B1
(en)
|
1999-05-14 |
2008-12-03 |
Genentech, Inc. |
TREATMENT WITH ANTI-ErbB2 ANTIBODIES
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
PT1189634E
(pt)
|
1999-06-25 |
2007-06-06 |
Genentech Inc |
Tratamento de cancro da próstata com anticorpos anti-erbb2.
|
|
US20030086924A1
(en)
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
|
US20040013667A1
(en)
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
MXPA02002037A
(es)
|
1999-08-27 |
2002-10-31 |
Genentech Inc |
Dosificaciones para el tratamiento con anticuerpos anti-erb2.
|
|
US20200048362A1
(en)
|
2000-03-16 |
2020-02-13 |
Immunogen, Inc. |
Methods of treatment using anti-erbb antibody-maytansinoid conjugates
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US6632979B2
(en)
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
|
AU6469601A
(en)
|
2000-05-19 |
2001-12-03 |
Genentech Inc |
Gene detection assay for improving the likelihood of an effective response to anerbb antagonist cancer therapy
|
|
US6984494B2
(en)
|
2000-08-15 |
2006-01-10 |
Genentech, Inc. |
Analytical method
|
|
IL156618A0
(en)
|
2000-12-28 |
2004-01-04 |
Altus Biologics Inc |
Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same
|
|
US6695940B2
(en)
|
2001-04-05 |
2004-02-24 |
Alan D. Devoe |
Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
|
|
EP1300146A1
(en)
|
2001-10-03 |
2003-04-09 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition for the treatment of animal mammary tumors
|
|
US20040048525A1
(en)
|
2002-01-28 |
2004-03-11 |
Sagucio Esteban N. |
Watercycle for wet rider
|
|
JP2005522514A
(ja)
|
2002-04-10 |
2005-07-28 |
ジェネンテック・インコーポレーテッド |
抗ｈｅｒ２抗体改変体
|
|
US6982719B2
(en)
|
2002-07-15 |
2006-01-03 |
Sun Microsystems, Inc. |
Switching sample buffer context in response to sample requests for real-time sample filtering and video generation
|
|
DK2263691T3
(da)
|
2002-07-15 |
2012-10-22 |
Hoffmann La Roche |
Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4)
|
|
US7129840B2
(en)
|
2002-09-03 |
2006-10-31 |
Ricoh Company, Ltd. |
Document security system
|
|
HUE033623T2
(en)
|
2002-09-11 |
2017-12-28 |
Genentech Inc |
protein purification
|
|
CA2506320A1
(en)
|
2002-11-21 |
2004-06-10 |
Genentech, Inc. |
Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
|
|
TW555245U
(en)
|
2003-01-29 |
2003-09-21 |
Hon Hai Prec Ind Co Ltd |
Cable connector assembly
|
|
ZA200507978B
(en)
|
2003-03-05 |
2007-03-28 |
Halozyme Inc |
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US20050025753A1
(en)
|
2003-04-30 |
2005-02-03 |
Wei Han |
Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells
|
|
JP4599355B2
(ja)
|
2003-07-28 |
2010-12-15 |
ジェネンテック， インコーポレイテッド |
プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減
|
|
CA2563341C
(en)
|
2004-04-08 |
2014-10-21 |
David B. Agus |
Erbb antagonists for pain therapy
|
|
US7195440B2
(en)
|
2004-05-27 |
2007-03-27 |
Lambert Charles F |
Agricultural silo auger system apparatus and method
|
|
CN114053429A
(zh)
|
2004-06-01 |
2022-02-18 |
健泰科生物技术公司 |
抗体-药物偶联物和方法
|
|
SV2006002143A
(es)
|
2004-06-16 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del cancer resistente al platino
|
|
KR20150140417A
(ko)
|
2004-07-22 |
2015-12-15 |
제넨테크, 인크. |
Ｈｅｒ２ 항체 조성물
|
|
EP1778728A2
(en)
|
2004-08-19 |
2007-05-02 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
BRPI0518086A
(pt)
|
2004-12-07 |
2008-10-28 |
Genentech Inc |
métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação
|
|
UA94899C2
(ru)
|
2005-01-21 |
2011-06-25 |
Дженентек, Инк. |
Фиксированное дозирование антител к her
|
|
CN101163503B
(zh)
|
2005-02-23 |
2013-05-08 |
健泰科生物技术公司 |
使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
|
|
WO2006096861A2
(en)
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
|
US20060212956A1
(en)
|
2005-03-14 |
2006-09-21 |
Genentech, Inc. |
Animal model of ligand activated HER2 expressing tumors
|
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
|
|
MY157955A
(en)
|
2005-07-06 |
2016-08-30 |
Hoffmann La Roche |
Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
|
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
US7700299B2
(en)
|
2005-08-12 |
2010-04-20 |
Hoffmann-La Roche Inc. |
Method for predicting the response to a treatment
|
|
EP1971367A4
(en)
|
2005-12-05 |
2010-04-07 |
Trinity Biosystems Inc |
METHOD AND COMPOSITIONS FOR THE NEEDLESS DELIVERY OF BINDING PARTNERS
|
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
|
WO2007145862A2
(en)
|
2006-06-05 |
2007-12-21 |
Genentech, Inc. |
Extending survival of cancer patients with elevated levels of egf or tgf-alpha
|
|
KR101136763B1
(ko)
|
2006-08-21 |
2012-04-24 |
에프. 호프만-라 로슈 아게 |
항-ｖｅｇｆ 항체를 이용한 종양 치료 방법
|
|
WO2008031531A1
(en)
*
|
2006-09-15 |
2008-03-20 |
F. Hoffmann-La Roche Ag |
Tumor therapy with a combination of anti-her2 antibodies
|
|
CN101680897B
(zh)
|
2007-03-02 |
2013-11-13 |
健泰科生物技术公司 |
基于低her3表达预测对her二聚化抑制剂的响应
|
|
EP1997534A1
(en)
|
2007-05-31 |
2008-12-03 |
Pierre Fabre Medicament |
Cancer treatment combination therapy comprising vinflunine and trastuzumab
|
|
ES2555784T3
(es)
|
2007-06-06 |
2016-01-08 |
F. Hoffmann-La Roche Ag |
Composición de un primer anticuerpo monoclonal no marcado, que se une a un antígeno de tumor y un segundo anticuerpo monoclonal que no tiene reacción cruzada y está marcado con un marcador de fluorescencia NIR
|
|
ES2417148T3
(es)
|
2007-06-08 |
2013-08-06 |
Genentech, Inc. |
Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
|
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
US8247397B2
(en)
|
2007-09-12 |
2012-08-21 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
|
EP3441402A1
(en)
|
2007-10-30 |
2019-02-13 |
Genentech, Inc. |
Antibody purification by cation exchange chromatography
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
US20090226455A1
(en)
|
2008-03-06 |
2009-09-10 |
Genentech, Inc. |
Combination therapy with c-met and her antagonists
|
|
CA2990929C
(en)
|
2008-03-18 |
2022-04-12 |
Genentech, Inc. |
Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
|
US9235334B2
(en)
|
2008-05-09 |
2016-01-12 |
Genesis Industries, Llc |
Managing landbases and machine operations performed thereon
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
EP2435071A1
(en)
|
2009-05-29 |
2012-04-04 |
F. Hoffmann-La Roche AG |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
MX2013006392A
(es)
|
2010-12-09 |
2013-12-06 |
Genentech Inc |
Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
|
|
WO2012120004A1
(en)
|
2011-03-07 |
2012-09-13 |
F. Hoffmann-La Roche Ag |
In vivo selection of therapeutically active antibodies
|
|
JP2012228007A
(ja)
*
|
2011-04-15 |
2012-11-15 |
Asmo Co Ltd |
バスバー装置、ステータ、モータ及びステータの製造方法
|
|
DK4234033T3
(da)
|
2011-10-14 |
2025-03-31 |
Hoffmann La Roche |
Anvendelser for og fremstillet artikel indbefattende HER2-dimeriseringshæmmeren pertuzumab
|
|
WO2013083810A1
(en)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
|
EP2793941A1
(en)
|
2011-12-23 |
2014-10-29 |
F.Hoffmann-La Roche Ag |
Articles of manufacture and methods for co-administration of antibodies
|
|
EP2858666B1
(en)
|
2012-06-08 |
2019-09-04 |
F.Hoffmann-La Roche Ag |
Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
|
|
CN102961745B
(zh)
*
|
2012-09-27 |
2015-02-18 |
苏州康聚生物科技有限公司 |
抗体组合物制剂及其应用
|
|
BR112015012644A2
(pt)
|
2012-11-30 |
2017-12-19 |
Hoffmann La Roche |
método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
|
|
US9180185B2
(en)
|
2013-01-11 |
2015-11-10 |
Hoffman-La Roche Inc. |
Combination therapy of anti-HER3 antibodies
|
|
SG11201508536PA
(en)
|
2013-04-16 |
2015-11-27 |
Genentech Inc |
Pertuzumab variants and evaluation thereof
|
|
CN105934253A
(zh)
|
2013-12-17 |
2016-09-07 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法
|
|
SG10201809411PA
(en)
|
2014-04-25 |
2018-11-29 |
Genentech Inc |
Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
|
|
WO2016011422A2
(en)
*
|
2014-07-17 |
2016-01-21 |
Czerniecki Brian J |
Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3
|
|
SG11201701821QA
(en)
|
2014-09-15 |
2017-04-27 |
Genentech Inc |
Antibody formulations
|
|
HK1243629A1
(zh)
|
2014-09-17 |
2018-07-20 |
基因泰克公司 |
包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
|
|
CN104784105A
(zh)
*
|
2015-04-17 |
2015-07-22 |
北京大学 |
一种单克隆抗体药物的凝胶组合物
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
EP3267657A1
(de)
|
2016-07-06 |
2018-01-10 |
Siemens Aktiengesellschaft |
Netzwerksystem, cloud-anschluss und verfahren zur identifikation von netzwerkgeräten
|
|
EP3534948A1
(en)
|
2016-11-04 |
2019-09-11 |
Genentech, Inc. |
Treatment of her2-positive breast cancer
|
|
CN110099926A
(zh)
|
2016-12-28 |
2019-08-06 |
豪夫迈·罗氏有限公司 |
晚期her2表达性癌症的治疗
|
|
HUE052551T2
(hu)
|
2017-01-17 |
2021-05-28 |
Genentech Inc |
Szubkután HER2 antitest készítmények
|
|
US11077189B2
(en)
|
2017-03-02 |
2021-08-03 |
Genentech Inc. |
Adjuvant treatment of HER2-positive breast cancer
|
|
WO2018200505A1
(en)
|
2017-04-24 |
2018-11-01 |
Genentech, Inc. |
Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
|
|
KR20230030621A
(ko)
|
2020-06-29 |
2023-03-06 |
제넨테크, 인크. |
퍼투주맙 + 트라스투주맙 고정 용량 조합
|
|
JP2023533813A
(ja)
|
2020-07-14 |
2023-08-04 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
一定用量配合剤のアッセイ
|
|
JP2024501445A
(ja)
|
2020-12-11 |
2024-01-12 |
ジェネンテック， インコーポレイテッド |
Ｈｅｒ２がんの処置のための併用療法
|